Neoplasia (New York, N.Y.) - JoVE Visualize

Showing results (481-490 of 2,753) with videos related to

Pageof 276

Sort By:

Neoplasia (New York, N.Y.)|November 9, 2013

Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeuticsMike Mattie, Ashley Christensen, Mi Sook Chang, et al.

Neoplasia (New York, N.Y.)|November 9, 2013

Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibitionSumin Han, J Chad Brenner, Aaron Sabolch, et al.

Neoplasia (New York, N.Y.)|November 8, 2014

Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activationSilvina Grasso, Elena Tristante, Miguel Saceda, et al.

Neoplasia (New York, N.Y.)|April 19, 2026

Characterizing the impact of MLL fusion variants and fusion partners on leukemia plasticity using a human CRISPR-engineered MLL-rearranged leukemia modelPia Radszuweit, Rahel Fitzel, Sarah Bruestl, et al.

Neoplasia (New York, N.Y.)|May 12, 2012

Transgenic overexpression of the proprotein convertase furin enhances skin tumor growthJian Fu, Daniel E Bassi, Jirong Zhang, et al.

Neoplasia (New York, N.Y.)|May 27, 2023

Translational considerations for immunotherapy clinical trials in pediatric neuro-oncologyJessica B Foster, Marta M Alonso, Elias Sayour, et al.

Neoplasia (New York, N.Y.)|May 19, 2026

Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancerMelani Luque, Miriam Morales-Gallego, Marta Sanz-Álvarez, et al.

Neoplasia (New York, N.Y.)|June 12, 2026

Tumor cell-intrinsic NSUN2 deficiency reprograms macrophages to sensitize non-small cell lung cancer to EGFR inhibitors by reversing immune evasionYueqin Wang, Jingyao Wei, Wenbin Xu, et al.

Neoplasia (New York, N.Y.)|April 14, 2026

PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapyHong Lou, David Langan, Nick Syracuse, et al.

Neoplasia (New York, N.Y.)|April 29, 2026

Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncologyHaixia Zhu, Jingjing Shao, Yaxuan Wang, et al.

Pageof 276

Showing results (481-490 of 2,753) with videos related to

Sort By:

Pageof 276

Neoplasia (New York, N.Y.)|November 9, 2013

Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeuticsMike Mattie, Ashley Christensen, Mi Sook Chang, et al.

Neoplasia (New York, N.Y.)|November 9, 2013

Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibitionSumin Han, J Chad Brenner, Aaron Sabolch, et al.

Neoplasia (New York, N.Y.)|November 8, 2014

Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activationSilvina Grasso, Elena Tristante, Miguel Saceda, et al.

Neoplasia (New York, N.Y.)|April 19, 2026

Characterizing the impact of MLL fusion variants and fusion partners on leukemia plasticity using a human CRISPR-engineered MLL-rearranged leukemia modelPia Radszuweit, Rahel Fitzel, Sarah Bruestl, et al.

Neoplasia (New York, N.Y.)|May 12, 2012

Transgenic overexpression of the proprotein convertase furin enhances skin tumor growthJian Fu, Daniel E Bassi, Jirong Zhang, et al.

Neoplasia (New York, N.Y.)|May 27, 2023

Translational considerations for immunotherapy clinical trials in pediatric neuro-oncologyJessica B Foster, Marta M Alonso, Elias Sayour, et al.

Neoplasia (New York, N.Y.)|May 19, 2026

Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancerMelani Luque, Miriam Morales-Gallego, Marta Sanz-Álvarez, et al.

Neoplasia (New York, N.Y.)|June 12, 2026

Tumor cell-intrinsic NSUN2 deficiency reprograms macrophages to sensitize non-small cell lung cancer to EGFR inhibitors by reversing immune evasionYueqin Wang, Jingyao Wei, Wenbin Xu, et al.

Neoplasia (New York, N.Y.)|April 14, 2026

PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapyHong Lou, David Langan, Nick Syracuse, et al.

Neoplasia (New York, N.Y.)|April 29, 2026

Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncologyHaixia Zhu, Jingjing Shao, Yaxuan Wang, et al.

Pageof 276